论文部分内容阅读
对20例呼吸衰竭(Ⅱ型)肺性脑病患者采用分组对照的方法,探讨纳洛酮的临床治疗效果。呼吸衰竭肺性脑病患者血液中β-内腓肽的含量明显升高,它为中枢性呼吸抑制剂,而纳洛酮是一种非专一性阿片受体竞争性拮抗剂,能对抗β-EP的作用,缓解呼吸抑制和高碳酸血症,改善低氧血症,改善脑皮层的供血情况,保护和恢复脑细胞的功能,它的作用明显优于呼吸兴奋剂,且用药简便,起效快,安全性高,副作用小。
Twenty cases of respiratory failure (type Ⅱ) patients with pulmonary encephalopathy were treated by group comparison to explore the clinical effect of naloxone. Respiratory failure patients with pulmonary encephalopathy in the blood β-endorphin levels were significantly increased, it is a central respiratory inhibitor, and naloxone is a non-specific antagonist of opioid receptor antagonists, β- The role of EP in relieving respiratory depression and hypercapnia, improving hypoxemia, improving blood supply to the cerebral cortex, and protecting and restoring the function of brain cells are obviously superior to respiratory stimulants and have the advantages of simple and effective administration Fast, safe, low side effects.